Get the Stockscreener App
558.44
2.61%
-14.94
After Hours:
558.00
-0.44
-0.08%
Regeneron Pharmaceuticals Inc stock is traded at $558.44, with a volume of 1.23M.
It is down -2.61% in the last 24 hours and down -0.81% over the past month.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
See More
Previous Close:
$573.38
Open:
$571.2
24h Volume:
1.23M
Relative Volume:
1.18
Market Cap:
$58.17B
Revenue:
$14.21B
Net Income/Loss:
$4.46B
P/E Ratio:
14.07
EPS:
39.68
Net Cash Flow:
$3.56B
1W Performance:
-3.83%
1M Performance:
-0.81%
6M Performance:
-21.07%
1Y Performance:
-50.65%
1-Day Range:
$552.81
$571.20
1-Week Range:
$552.81
$588.70
52-Week Range:
$476.49
$1,170.58
Regeneron Pharmaceuticals Inc Stock (REGN) Company Profile
Name
Regeneron Pharmaceuticals Inc
Sector
Industry
Phone
(914) 847-7000
Address
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY
Compare REGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
REGN
Regeneron Pharmaceuticals Inc
|
558.44 | 60.77B | 14.21B | 4.46B | 3.56B | 39.68 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.25 | 101.56B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
455.03 | 59.25B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
768.00 | 45.95B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
346.45 | 37.61B | 3.81B | -644.79M | -669.77M | -6.24 |
Regeneron Pharmaceuticals Inc Stock (REGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-14-25 | Initiated | Rothschild & Co Redburn | Buy |
| Jun-30-25 | Downgrade | Argus | Buy → Hold |
| May-30-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| May-30-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| May-14-25 | Upgrade | Citigroup | Neutral → Buy |
| Apr-22-25 | Resumed | Cantor Fitzgerald | Overweight |
| Feb-05-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Jan-16-25 | Downgrade | UBS | Buy → Neutral |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Nov-14-24 | Initiated | Citigroup | Neutral |
| Sep-24-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Mar-12-24 | Initiated | Bernstein | Outperform |
| Jan-12-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-03-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Aug-21-23 | Upgrade | Canaccord Genuity | Hold → Buy |
| Aug-21-23 | Reiterated | Oppenheimer | Perform |
| Jun-28-23 | Downgrade | Canaccord Genuity | Buy → Hold |
| Mar-27-23 | Upgrade | SVB Securities | Market Perform → Outperform |
| Mar-24-23 | Upgrade | Jefferies | Hold → Buy |
| Mar-23-23 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Jan-30-23 | Upgrade | Cowen | Market Perform → Outperform |
| Jan-20-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-26-22 | Downgrade | Raymond James | Mkt Perform → Underperform |
| Oct-17-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Sep-09-22 | Upgrade | Jefferies | Underperform → Hold |
| Sep-09-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jul-25-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Neutral |
| Jun-06-22 | Initiated | Jefferies | Underperform |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Jan-05-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Jan-03-22 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Dec-15-21 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Dec-09-21 | Resumed | Wells Fargo | Overweight |
| Dec-07-21 | Resumed | Cowen | Market Perform |
| Dec-06-21 | Initiated | Goldman | Buy |
| Nov-19-21 | Resumed | BMO Capital Markets | Outperform |
| Nov-05-21 | Downgrade | The Benchmark Company | Buy → Hold |
| Jun-29-21 | Initiated | H.C. Wainwright | Buy |
| Jan-25-21 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Jan-13-21 | Upgrade | The Benchmark Company | Hold → Buy |
| Jan-08-21 | Upgrade | Citigroup | Neutral → Buy |
| Oct-05-20 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Aug-20-20 | Downgrade | The Benchmark Company | Buy → Hold |
| Jul-09-20 | Upgrade | SunTrust | Hold → Buy |
| May-26-20 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Apr-28-20 | Downgrade | Citigroup | Buy → Neutral |
| Apr-17-20 | Upgrade | The Benchmark Company | Hold → Buy |
| Apr-08-20 | Initiated | The Benchmark Company | Hold |
| Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
| Feb-27-20 | Initiated | Barclays | Overweight |
| Feb-26-20 | Upgrade | Canaccord Genuity | Hold → Buy |
| Feb-26-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Feb-25-20 | Upgrade | Jefferies | Hold → Buy |
| Feb-11-20 | Upgrade | Argus | Hold → Buy |
| Dec-24-19 | Initiated | Raymond James | Mkt Perform |
| Dec-16-19 | Downgrade | Evercore ISI | Outperform → In-line |
| Dec-13-19 | Upgrade | Credit Suisse | Neutral → Outperform |
| Nov-12-19 | Initiated | SunTrust | Hold |
| Nov-07-19 | Upgrade | Citigroup | Neutral → Buy |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Sep-23-19 | Upgrade | Guggenheim | Neutral → Buy |
View All
Regeneron Pharmaceuticals Inc Stock (REGN) Latest News
Royal Bank of Canada Trims Stake in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
What's Happening With Regeneron Pharmaceuticals Stock On Monday? - Benzinga
Regeneron’s allergen-blocking antibodies score phase 3 wins against cat, pollen allergies - Fierce Biotech
Samlyn Capital LLC Makes New $29.12 Million Investment in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Transcript : Regeneron Pharmaceuticals, Inc. Presents at Morgan Stanley 23rd Annual Global Healthcare Conference, Sep-08-2025 07 - MarketScreener
Regeneron Pharmaceuticals Said Phase 3 Trials of Invetigational Allergy Drug Meets Primary, Secondary Endpoints - MarketScreener
Regeneron Pharmaceuticals, Inc. $REGN Shares Purchased by Nissay Asset Management Corp Japan ADV - MarketBeat
Regeneron advances allergy pipeline with positive Phase 3 trial results By Investing.com - Investing.com Canada
Regeneron advances allergy pipeline with positive Phase 3 trial results - Investing.com
Regeneron Pharmaceuticals, Inc. Advances Allergy Pipeline with Two Positive Phase 3 Trials Evaluating First-In-Class Antibody-Blockers of Cat and Birch Allergies - MarketScreener
Regeneron advances allergy pipeline with two positive Phase 3 trials evaluating antibody-blockers - MarketScreener
Regeneron antibody treatments show promise against cat and birch allergies - Investing.com
Regeneron Says Experimental Therapy Reduced Symptoms Of Cat, Birch Allergies In Late-Stage Trials - Stocktwits
Trading Recap: Is Regeneron Pharmaceuticals Inc. a cyclical or defensive stockJuly 2025 Update & Entry Point Confirmation Signals - beatles.ru
Hancock Whitney Corp Sells 5,650 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Global Atopic Dermatitis Market Set to Transform with - openPR.com
Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Banque Transatlantique SA - MarketBeat
Flputnam Investment Management Co. Sells 5,992 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Shares Bought by Adage Capital Partners GP L.L.C. - MarketBeat
2 Beaten-Down Stocks to Buy on the Dip - sharewise.com
2 Beaten-Down Stocks to Buy on the Dip - The Motley Fool
Regeneron Pharmaceuticals, Inc. $REGN Shares Purchased by DnB Asset Management AS - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Shares Bought by Gotham Asset Management LLC - MarketBeat
Focus Partners Advisor Solutions LLC Acquires Shares of 849 Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by MAI Capital Management - MarketBeat
Regeneron Pharmaceuticals, Inc. (REGN): A Bull Case Theory - MSN
How Cemdisiran’s Phase 3 Success at Regeneron Pharmaceuticals (REGN) Has Changed Its Investment Story - simplywall.st
GW Henssler & Associates Ltd. Has $12.91 Million Stock Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Will Regeneron Pharmaceuticals Inc. outperform the marketMarket Activity Report & Low Risk Profit Maximizing Plans - Newser
Machine Learning Models Forecast Regeneron Pharmaceuticals Inc. UptickWatch List & Reliable Trade Execution Plans - beatles.ru
Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Alliancebernstein L.P. - MarketBeat
How Positive Phase 3 Cemdisiran Results at Regeneron (REGN) Have Changed Its Investment Story - Yahoo Finance
Regeneron Pharmaceuticals, Inc. $REGN Shares Purchased by AQR Capital Management LLC - MarketBeat
Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Rating Upgraded by Raymond James Financial - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN is Armistice Capital LLC's 10th Largest Position - MarketBeat
Regeneron Pharmaceuticals Inc. Stock Underperforms Friday When Compared To Competitors Despite Daily Gains - 富途牛牛
How to forecast Regeneron Pharmaceuticals Inc. trends using time seriesVolume Spike & Fast Exit Strategy with Risk Control - Newser
RHHBY Posts Positive Data on Vabysmo in nAMD at Euretina Congress - The Globe and Mail
What makes Regeneron Pharmaceuticals Inc. stock price move sharplyGap Down & Stock Timing and Entry Methods - Newser
Will Regeneron Pharmaceuticals Inc. benefit from seasonalityJuly 2025 Momentum & Community Consensus Trade Signals - خودرو بانک
Regeneron Pharmaceuticals, Inc. $REGN Stake Boosted by Amundi - MarketBeat
Regeneron Pharmaceuticals (REGN): Undervalued Innovator with Asymmetric Upside in 2025–2026 - AInvest
Regeneron Pharmaceuticals, Inc. $REGN Stock Position Lessened by Vident Advisory LLC - MarketBeat
Is a relief rally coming for Regeneron Pharmaceuticals Inc. holdersM&A Rumor & Safe Entry Zone Identification - Newser
Ieq Capital LLC Raises Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Can Regeneron Pharmaceuticals Inc. expand its profit marginsDividend Hike & Free Safe Entry Trade Signal Reports - خودرو بانک
Sanofi’s amlitelimab hits phase III endpoints in atopic dermatitis - BioWorld MedTech
Landscape Capital Management L.L.C. Takes Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron’s Strategic Visibility in Upcoming Investor Conferences: A Glimpse into Innovation and Growth - AInvest
Regeneron Announces Updated Presentation Time for Upcoming Investor Conference - MarketScreener
Leading Biotech Regeneron Announces New Time for Morgan Stanley Global Healthcare Conference - Stock Titan
Regeneron Pharmaceuticals Inc Stock (REGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.67%
8.71%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):